- Home
- OGI vs CRVS Comparison
OGI vs CRVS Comparison
Compare OGI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OGI | CRVS |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.5M | 634.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | OGI | CRVS |
|---|---|---|
| Price | $2.04 | $7.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 12-16-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $186,075,713.00 | N/A |
| Revenue This Year | $13.11 | N/A |
| Revenue Next Year | $12.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $2.54 |
| 52 Week High | $2.24 | $9.60 |
Technical Indicators
Market Signals| Indicator | OGI | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 37.13 |
| Support Level | $1.97 | $7.47 |
| Resistance Level | $2.24 | $9.60 |
| Average True Range (ATR) | 0.15 | 0.54 |
| MACD | 0.05 | -0.17 |
| Stochastic Oscillator | 69.33 | 3.29 |
Price Performance
Historical ComparisonAbout OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).